hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06278402, orgStudyIdInfo id: JinnahH, briefTitle: Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi., statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2024-01-06, completionDateStruct date: 2024-01-16, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Jinnah Hospital, class: OTHER, descriptionModule briefSummary: To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth \>75%). Efficacy will be considered if re-growth ≥ 2., conditionsModule conditions: Alopecia Areata, conditions: Alopecia Totalis, conditions: Alopecia Universalis, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This study includes patients with moderate to severe Alopecia Areata, totalis and universalis. The efficacy of JAK 1/3 inhibitor, Tofacitinib will be assessed by using SALT score (Severity of Alopecia Tool) at Baseline, 06 weeks, 12 weeks and 24 weeks. Oral Tofacitinib given at a dose of 5 mg twice daily after relevant investigations. The data will be analyzed in SPSS version 23., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Tofacitinib, outcomesModule primaryOutcomes measure: Alopecia, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Misbah Zari Qadir, city: Karachi, state: Sindh, country: Pakistan, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06278376, orgStudyIdInfo id: f/2023/045, briefTitle: Evaluation of Diagnoses and Clinical Outcomes in Children Undergoing MRI Scans, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-04-25, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Jessa Hospital, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the indications and therapeutical consequences of MRI scans of (young) children undergoing risky remote anaesthesia. The investigators want to aim for a clear indication in children undergoing MRI in the future before undergoing possible unnecessary procedures and MRI scans., conditionsModule conditions: Magnetic Resonance Imaging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 410, type: ACTUAL, outcomesModule primaryOutcomes measure: Incidence, secondaryOutcomes measure: Therapeutical implications: diagnosis, secondaryOutcomes measure: Therapeutical implications: treatment, secondaryOutcomes measure: Clinical indications, secondaryOutcomes measure: Evaluation of body part, secondaryOutcomes measure: Evaluation of symptoms, secondaryOutcomes measure: Clinical outcome: adverse event, secondaryOutcomes measure: Clinical outcome: surgery, secondaryOutcomes measure: Clinical outcome: admission to hospital, secondaryOutcomes measure: Clinical outcome: mortality, secondaryOutcomes measure: Evaluation of age, secondaryOutcomes measure: Influence of COVID-19 pandemic, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Jessa hospital, city: Hasselt, zip: 3500, country: Belgium, geoPoint lat: 50.93106, lon: 5.33781, hasResults: False
protocolSection identificationModule nctId: NCT06278350, orgStudyIdInfo id: D2570-201, briefTitle: Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-04, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: InventisBio Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis ., conditionsModule conditions: Plaque Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: D-2570, interventions name: Placebo, outcomesModule primaryOutcomes measure: Percentage of subjects with at least 75% improvement in PASI, secondaryOutcomes measure: Percentage of subjects with at least 75% improvement in PASI, secondaryOutcomes measure: Percentage of subjects with at least 90% improvement in PASI, secondaryOutcomes measure: Percentage of subjects with 100% improvement in PASI, secondaryOutcomes measure: Percentage improvement in PASI, secondaryOutcomes measure: Percentage of subjects with a PGA, secondaryOutcomes measure: The main PK parameters ：Time to maximum measured plasma concentration（Tmax）, secondaryOutcomes measure: The main PK parameters ：Peak Plasma Concentration（Cmax), secondaryOutcomes measure: The main PK parameters：Area under the plasma concentration versus time curve（AUC）, secondaryOutcomes measure: The main PK parameters：Vz/F (apparent volume of distribution), secondaryOutcomes measure: The main PK parameters： Half-life（t1/2）, secondaryOutcomes measure: The main PK parameters： Mean Residence Time (MRT), secondaryOutcomes measure: The main PK parameters：CL/F (apparent clearance), secondaryOutcomes measure: Weight and height will be combined to report BMI in kg/m^2, secondaryOutcomes measure: Incidence and severity of AEs based on NCI CTCAE V5.0, secondaryOutcomes measure: Incidence and severity of TEAEs based on NCI CTCAE V5.0, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Jianzhong Zhang, role: CONTACT, phone: 13911815813, email: rmzjz@126.com, contacts name: Cheng Zhou, role: CONTACT, phone: 010-88325470, email: zhoucheng@live.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06278311, orgStudyIdInfo id: 20235761, briefTitle: Correlation of Toxins With Gastrointestinal (GI) and Overall Health, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Vibrant America Clinical Lab, class: INDUSTRY, collaborators name: Los Angeles Integrative Gastroenterology and Nutrition, Inc, descriptionModule briefSummary: The goal of this observational study is to evaluate the levels of urinary environmental toxins, heavy metals, PFAS and mycotoxins with gastrointestinal (GI) and overall health., conditionsModule conditions: Gastrointestinal Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Determination of the Total Toxicity score, primaryOutcomes measure: Determination of the Symptom score, primaryOutcomes measure: Determination of the Diagnosis score, secondaryOutcomes measure: Determination of individual scores, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Los Angeles Integrative Gastroenterology and Nutrition, Inc, city: Los Angeles, state: California, zip: 90067, country: United States, contacts name: Dr. Farshid S Rahbar, MD, role: CONTACT, phone: 310-289-8000, email: Research@laintegrativegi.com, contacts name: Dr. Farshid S Rahbar, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Vibrant America Clinical Lab, city: Santa Clara, state: California, zip: 95054, country: United States, contacts name: Hari K Krishnamurthy, MS, role: CONTACT, phone: 866-364-0963, email: hari@vibrantsci.com, contacts name: Hari K Krishnamurthy, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.35411, lon: -121.95524, hasResults: False
protocolSection identificationModule nctId: NCT06278298, orgStudyIdInfo id: REC/012/003318, briefTitle: Different Level of ECSWT in Post Mastectomy Lymphedema, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: to investigate the effectiveness of different dosages of ECSW in the treatment of post mastectomy lymphedema volume and quality of life (Qol), conditionsModule conditions: Lymphedema of Upper Limb, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Shockwave, interventions name: CDT, outcomesModule primaryOutcomes measure: lymphedema volume, primaryOutcomes measure: skin thickness of the arm, eligibilityModule sex: FEMALE, minimumAge: 30 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cairo University, city: Giza, state: Dokki, zip: 12612, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06278285, orgStudyIdInfo id: 21-AOIP-01, briefTitle: Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery, acronym: Maigrir_OT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Nice, class: OTHER, descriptionModule briefSummary: Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Blood GLP1, interventions name: Blood No treated GLP1, outcomesModule primaryOutcomes measure: Rate of oxytocin, secondaryOutcomes measure: Fibrosis rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Nice - Hôpital de l'Archet, status: RECRUITING, city: Nice, state: Alpes-maritimes, zip: 06200, country: France, contacts name: Roux Christian, PhD, role: CONTACT, phone: +33492039220, email: roux.c@chu-nice.fr, contacts name: Iannelli Antonio, PhD, role: CONTACT, phone: +33492035900, email: iannelli.a@chu-nice.fr, contacts name: Iannelli Antonio, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70313, lon: 7.26608, hasResults: False
protocolSection identificationModule nctId: NCT06278272, orgStudyIdInfo id: AIPEI, briefTitle: AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2024-01-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Changhai Hospital, class: OTHER, descriptionModule briefSummary: Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients. A total of 504 patients with CP who underwent fecal elastase-1 test and contrast-enhanced CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. The investigators aim to establish a fully automated workflow to establish a PEI classification model based on radiomic features, semantic features and deep learning features on enhanced CT images for evaluating the severity of PEI., conditionsModule conditions: Chronic Pancreatitis, conditions: Exocrine Pancreatic Insufficiency, conditions: Machine Learning, conditions: Deep Learning, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 504, type: ACTUAL, outcomesModule primaryOutcomes measure: Classification of pancreatic exocrine insufficiency, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changhai Hospital, city: Shanghai, zip: 200433, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06278259, orgStudyIdInfo id: P.T.REC/012/005023, briefTitle: Telerehabilitation Program Bases Aerobic and Baduanjin Exercises in Post Stroke Elderly Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: It is an interventional study in which 60 stroke patients estimated to enroll according to random allocation and will divided into two groups. The study group participants will involve in Telerehabilitation sessions will be based on low-impact rhythmic movements, guided by video with the Baduanjin exercise program ,the control group will receive the same aerobic exercises only, conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Telerehabilitation program bases aerobic and Baduanjin exercises, interventions name: Telerehabilitation program bases aerobic exercises, outcomesModule primaryOutcomes measure: physical function, secondaryOutcomes measure: Cognitive function, secondaryOutcomes measure: sleep quality, secondaryOutcomes measure: participants' satisfaction with the program, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 75 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Physical Therapy, status: RECRUITING, city: Cairo, state: Dokki, zip: 11432, country: Egypt, contacts name: marwa M elsayed, phd, role: CONTACT, phone: 01156033818, phoneExt: 02, email: marwadd999@gmail.com, contacts name: marwa M elsayed, ph.d, role: CONTACT, phone: 01156033818, phoneExt: 02, email: marwadd999@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06278246, orgStudyIdInfo id: 050/2021, briefTitle: Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2029-02, completionDateStruct date: 2029-02, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Centre for Addiction and Mental Health, class: OTHER, descriptionModule briefSummary: Within the schizophrenia population, there are individuals that respond to first-line antipsychotic treatments while others do not. The availability of muscarinic M4 subtype receptors (M4R) may play a role as to whether a person with schizophrenia is responsive to first-line antipsychotics or not. The goal of this observational study is to compare the availability of M4R in antipsychotic-free patients with schizophrenia and matched healthy controls. In addition, M4R availability in schizophrenia patients will be examined in relation to response to first line antipsychotics and clinical and cognitive measures. This study may help better understand antipsychotic resistance in schizophrenia and lead to the development of new treatment options, particularly for cognitive deficits and negative symptoms., conditionsModule conditions: Schizophrenia, conditions: Schizophreniform Disorders, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: PET Scan, outcomesModule primaryOutcomes measure: M4 receptor expression, primaryOutcomes measure: Clinical Data Statistical Analysis, secondaryOutcomes measure: Statistical Analysis of Cognitive Data, secondaryOutcomes measure: Statistical Analysis of Psychopathological Personality Traits in Health Control Group, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre for Addiction and Mental Health, city: Toronto, state: Ontario, zip: M5T1R8, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06278233, orgStudyIdInfo id: 2023/85-70, briefTitle: Bihemispheric Transcranial Direct Current Stimulation* on Speech Fluency, acronym: TDCS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Biruni University, class: OTHER, descriptionModule briefSummary: It will be determined whether bihemispheric stimulation (anodal to the left IFG and cathodal to the right IFG) is used with fluency-facilitating conditions for 5 consecutive days in individuals with stuttering and whether there is a difference in terms of the effects seen in speech fluency compared to the sham condition., conditionsModule conditions: Stuttering, Adult, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: In this study, a double-blind, randomized controlled research design from experimental research methods will be applied., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: One researcher not involved in any aspect of the study will randomize participants to the sham and tDCS study arms using blocked randomization. To ensure blinding, one researcher will record the administration of the tDCS and assessments, while independent speech-language pathologists will monitor the assessment recordings and score the test items., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial direct current stimulation, outcomesModule primaryOutcomes measure: Disfluent syllables, secondaryOutcomes measure: Stuttering Severity Instrument- Fourth Edition (SSI-IV) score, secondaryOutcomes measure: The Overall Assessment of the Speaker's Experience of Stuttering (OASES) score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Biruni University, status: RECRUITING, city: Istanbul, state: Zeytinburnu, zip: 34015, country: Turkey, contacts name: Feyzanur Ocak, Slp, role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06278220, orgStudyIdInfo id: Corneal HOA, briefTitle: Scheimpflug Versus Placido-disc System in Evaluation of Corneal Higher-Order Aberrations, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2027-02, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Aim of work:To assess the agreement between placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam ) regard measuring corneal higher order aberrations before and after LASIK., conditionsModule conditions: Corneal Higher-order Aberrations, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam ), outcomesModule primaryOutcomes measure: Agreement between placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (pentacam), secondaryOutcomes measure: Changes in high order aberrations after LASIK., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Naglaa Moustafa, city: Assiut, country: Egypt, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False